Charles River Laboratories International, Inc. and Curigin, a Korean biotechnology company developing innovative oncolytic ribonucleic acid interference (RNAi) gene therapies, announced a collaboration for adenoviral vector production. The gene therapy developer will leverage Charles River’s market-leading expertise in contract development and manufacturing organization (CDMO) solutions to support its preclinical and clinical trials.
Curigin develops anticancer gene therapy products that utilize innovative genetically engineered viruses and novel RNAi technology to quickly and accurately block key disease-specific genetic signal pathways, effectively switching off genes responsible for tumor growth. These gene therapies serve an unmet clinical need and can be offered to patients who have not been treated with conventional cancer drugs.